Robert J. Gould

Dr. Gould served as President and CEO of Fulcrum Therapeutics, Inc., a privately financed drug discovery and development company with a focus on genetically defined diseases, from its founding in 2016 until retirement in 2021. Prior to Fulcrum, Dr. Gould was President and CEO of Epizyme, Inc., where he led the company through a successful public offering. From November 2006 to March 2010, Dr. Gould served as Director of Novel Therapeutics at the Broad Institute of MIT and Harvard. Previously, Dr. Gould was Vice President, Licensing and External Research at Merck Research Laboratories, where he held a variety of leadership positions during his 23-year tenure. Dr. Gould received a B.A. in chemistry from Spring Arbor College, a Ph.D. in biochemistry from the University of Iowa, and completed postdoctoral studies at Johns Hopkins University. Dr. Gould also serves on the boards of Fulcrum, Turnstone Biologics and Spring Arbor University.